US EditionPublished • loading... • Updated
Eris Lifesciences to consolidate its stake in Swiss Parenterals
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Eris Lifesciences to consolidate its stake in Swiss Parenterals
Eris Lifesciences announced that its Board of Directors has approved the acquisition of the balance 30% stake in Swiss Parenterals Limited, a subsidiary. The proposed transaction will be effected as a share swap, i.e. through a preferential issuance of Eris equity shares to the seller Naishadh Shah, thereby making him a Top-10 shareholder of Eris and an integral part of Eris’ senior management team with long-term alignment. Commenting on the acq…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
